New research findings have been released by Abbott regarding its TRILUMINATE clinical study for their TriClip system.

The Pivotal trial was conducted with the aim to evaluate the success and safety level of their transcatheter edge-to-edge repair system when used as an alternative therapy for those suffering from acute TR. Individuals with this condition have a much higher chance of having to endure open-heart surgery, so Abbott is developing the TriClip system as a possible substitute for this.

“the TriClip system outperformed the control, primarily down to the increase in quality of life“

The research revealed that the TriClip system outperformed the control, primarily down to the increase in quality of life.

During the experiment, 87% of those in the TriClip treatment group saw a substantial decrease in TR, as opposed to less than 5% of those who received no treatment at all.

Abbott’s TEER device also proved to operate with a high level of safety.

Michael Dale, VP of the structural heart division at Abbott explained that this product “is the first minimally invasive device therapy for the treatment of [TR] to provide durable improvements in severity and quality of life.”